Ironwood Pharms logo

Ironwood Pharms

Stock
Stock
Ticker: IRWD
IRWD

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Ironwood Pharms is $594.86M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Ironwood Pharms is 4.69. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Ironwood Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.767. EPS indicates the company's profitability on a per-share basis.
Currently, 4 analysts cover Ironwood Pharms's stock, with a consensus target price of $6.10. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Ironwood Pharms reported a revenue of $389.32M.
Ironwood Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $237.91M. EBITDA measures the company's overall financial performance.
Ironwood Pharms has a free cash flow of $185.55M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Ironwood Pharms employs approximately 100 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Ironwood Pharms is 159.10M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$594.86M
EPS (TTM) 
$0.767
Free Float 
159.10M
P/E ratio (TTM) 
4.69
Revenue (TTM) 
$389.32M
EBITDA (TTM) 
$237.91M
Free Cashflow (TTM) 
$185.55M

Pricing

1D span
$3.772$3.799
52W span
$1.43$5.76

Analyst Ratings

The price target is $6.10 and the stock is covered by 4 analysts.

Buy

2

Hold

2

Sell

0

Information

Ironwood Pharmaceuticals, Inc. is a biotechnology company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Employees
100
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
IRWD

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation